List all articles in the database by descending article_id

GET /articles/?page=1346
HTTP 200 OK
Allow: GET, POST, HEAD, OPTIONS
Content-Type: application/json
Vary: Accept

{
    "count": 15514,
    "next": "http://api.gregory-ms.com/articles/?page=1347",
    "previous": "http://api.gregory-ms.com/articles/?page=1345",
    "results": [
        {
            "article_id": 2093,
            "title": "Changes in leptin, serotonin, and cortisol after eight weeks of aerobic exercise with probiotic intake in a cuprizone-induced demyelination mouse model of multiple sclerosis",
            "summary": "<div><p>Cytokine. 2021 May 24;144:155590. doi: 10.1016/j.cyto.2021.155590. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">BACKGROUND: Multiple sclerosis (MS) is the most common non-traumatic neurological cause of disability in young adults. Physical activity, particularly exercise training, is an evidence-based approach to managing symptoms, restoring function, and improving overall wellness in people with MS. As well, the use of probiotics can be effective in reducing the damage from inflammation in MS patients.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">OBJECTIVE: The study aimed to address changes in leptin, serotonin, and cortisol following eight weeks of aerobic exercise along with probiotic intake in a cuprizone-induced demyelination mouse model of MS.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">METHODS: Mice were exposed to cuprizone for 12 weeks. After 5 weeks, beam and performance tests were performed on them. The mice (n = 5 per group) were randomly divided into five groups: control (C), MS, MS with exercise (MS + Exe), MS with probiotic (MS + Prob), and MS with probiotic and exercise (MS + Prob + Exe). Exercise groups performed aerobic exercises 5 days a week, 10 min in the first week, 20 min in the second week, and 30 min daily in the third week until the eighth week. In the probiotic groups, the mice received probiotic by gavage. They were sacrificed after 3 months. Biochemical and molecular biology analyses were performed.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">RESULTS: The results showed that leptin gene expression values in the MS + Prob + Exe, MS + Prob, and MS + Exe groups showed a decrease compared to the MS group, but the reduction was not significant (p &gt; 0.05). Also, the leptin Elisa test in these intervention groups showed a significant decrease (P &lt; 0.05). The serotonin gene expression values in the MS + Prob + Exe, MS + Prob, and MS + Exe groups were increased compared to the MS group, but the increase was not significant (p &gt; 0.05). Furthermore, the serotonin Elisa test in these intervention groups showed a significant increase (P &lt; 0.05). The cortisol Elisa test values in the MS + Exe and MS + Prob groups exhibited a decrease compared to the MS group, but the reduction was not significant (p &gt; 0.05).</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSION: Overall, these results suggest that lifestyle interventions can be effective in improving pathological factors in patients with MS.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34049259/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210529054008&amp;v=2.14.4\">34049259</a> | DOI:<a href=\"https://doi.org/10.1016/j.cyto.2021.155590\">10.1016/j.cyto.2021.155590</a></p></div>",
            "link": "https://pubmed.ncbi.nlm.nih.gov/34049259/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x",
            "published_date": "2021-01-08T00:00:00Z",
            "source": "PubMed",
            "publisher": "Elsevier BV",
            "container_title": "Cytokine",
            "authors": [
                {
                    "url": "http://api.gregory-ms.com/authors/46163/",
                    "family_name": "Sajedi",
                    "given_name": "Donya",
                    "ORCID": null
                },
                {
                    "url": "http://api.gregory-ms.com/authors/46164/",
                    "family_name": "Shabani",
                    "given_name": "Ramin",
                    "ORCID": null
                },
                {
                    "url": "http://api.gregory-ms.com/authors/46165/",
                    "family_name": "Elmieh",
                    "given_name": "Alireza",
                    "ORCID": null
                }
            ],
            "relevant": null,
            "ml_prediction_gnb": false,
            "ml_prediction_lr": false,
            "discovery_date": "2021-05-29T09:40:09Z",
            "noun_phrases": [
                "Changes",
                "leptin",
                "cortisol",
                "eight weeks",
                "aerobic exercise",
                "probiotic intake",
                "a cuprizone-induced demyelination mouse model",
                "multiple sclerosis"
            ],
            "doi": "10.1016/j.cyto.2021.155590",
            "access": "restricted",
            "takeaways": " Multiple sclerosis is the most common non-traumatic neurological cause of disability in young adults . Exercise and probiotics can be effective in reducing the damage from inflammation in MS patients ."
        },
        {
            "article_id": 2092,
            "title": "The Neurologist as an Agent of Exercise Rehabilitation in Multiple Sclerosis",
            "summary": "<div><p>Exerc Sport Sci Rev. 2021 May 28. doi: 10.1249/JES.0000000000000262. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">This review hypothesizes that the neurologist represents the linchpin of exercise behavior change within comprehensive multiple sclerosis (MS) care settings. This is based on a series of recent papers that developed actionable practice models for accomplishing such behavior change through the neurologist as the primary agent. This provides tangible, next steps for exercise promotion in MS.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34049322/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210529054008&amp;v=2.14.4\">34049322</a> | DOI:<a href=\"https://doi.org/10.1249/JES.0000000000000262\">10.1249/JES.0000000000000262</a></p></div>",
            "link": "https://pubmed.ncbi.nlm.nih.gov/34049322/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x",
            "published_date": "2021-09-30T23:00:00Z",
            "source": "PubMed",
            "publisher": "Ovid Technologies (Wolters Kluwer Health)",
            "container_title": "Exercise and Sport Sciences Reviews",
            "authors": [
                {
                    "url": "http://api.gregory-ms.com/authors/621/",
                    "family_name": "Motl",
                    "given_name": "Robert W.",
                    "ORCID": null
                },
                {
                    "url": "http://api.gregory-ms.com/authors/3397/",
                    "family_name": "Sandroff",
                    "given_name": "Brian M.",
                    "ORCID": null
                },
                {
                    "url": "http://api.gregory-ms.com/authors/15368/",
                    "family_name": "Richardson",
                    "given_name": "Emma V.",
                    "ORCID": "http://orcid.org/0000-0001-7409-778X"
                }
            ],
            "relevant": null,
            "ml_prediction_gnb": false,
            "ml_prediction_lr": false,
            "discovery_date": "2021-05-29T09:40:09Z",
            "noun_phrases": [
                "The Neurologist",
                "an Agent",
                "Exercise Rehabilitation",
                "Multiple Sclerosis"
            ],
            "doi": "10.1249/JES.0000000000000262",
            "access": "open",
            "takeaways": " The neurologist represents the linchpin of exercise behavior change within comprehensive multiple sclerosis care settings . This provides tangible, next steps for exercise promotion in MS ."
        },
        {
            "article_id": 2091,
            "title": "PedsQL Multiple Sclerosis Module Domain and Item Development: Qualitative Methods",
            "summary": "<div><p>J Child Neurol. 2021 May 28:8830738211015016. doi: 10.1177/08830738211015016. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">BACKGROUND: The objective of this qualitative methods study was to develop the domains and items to support the content validity for the Pediatric Quality of Life Inventory (PedsQL) Multiple Sclerosis Module for youth with pediatric-onset multiple sclerosis.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">METHODS: A literature review of multiple sclerosis-specific questionnaires and clinical research was conducted to generate domains. An expert panel composed of 12 neurologists who were pediatric-onset multiple sclerosis specialists provided feedback on the conceptual framework. Focus interviews with 9 youth with pediatric-onset multiple sclerosis and 6 parents were conducted to develop the relevant domains and item content from the patient and parent perspective. In the cognitive interviews phase, 9 youth with pediatric-onset multiple sclerosis and 6 parents provided feedback on item content, relevance, importance, and understandability of the pediatric-onset multiple sclerosis-specific domains and items. The final interview phase with 5 youth with pediatric-onset multiple sclerosis and 5 parents comprised a pilot testing of the new PedsQL MS Module.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">RESULTS: Eighteen domains were derived from the qualitative methods with item content saturation achieved at 100 items based on 40 interviews with 23 youth with pediatric-onset multiple sclerosis aged 10-21 years and 17 parents. The domains derived include general fatigue, sleep/rest fatigue, cognitive functioning, tingling sensations, numbness sensations, physical weakness, pain, speech, balance, fine motor, vision, urination, constipation, bowel incontinence, worry, communication, treatment, and medicines.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSIONS: Qualitative methods involving 23 youth with pediatric-onset multiple sclerosis and 17 parents in the domain and item development process support the content validity for the new PedsQL MS Module. Future plans include a national field test of the PedsQL MS Module scales and items.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34048290/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210528202008&amp;v=2.14.4\">34048290</a> | DOI:<a href=\"https://doi.org/10.1177/08830738211015016\">10.1177/08830738211015016</a></p></div>",
            "link": "https://pubmed.ncbi.nlm.nih.gov/34048290/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x",
            "published_date": "2021-01-09T00:00:00Z",
            "source": "PubMed",
            "publisher": "SAGE Publications",
            "container_title": "Journal of Child Neurology",
            "authors": [
                {
                    "url": "http://api.gregory-ms.com/authors/4225/",
                    "family_name": "Mar",
                    "given_name": "Soe",
                    "ORCID": null
                },
                {
                    "url": "http://api.gregory-ms.com/authors/17560/",
                    "family_name": "Newland",
                    "given_name": "Pamela",
                    "ORCID": null
                },
                {
                    "url": "http://api.gregory-ms.com/authors/46159/",
                    "family_name": "Gaudioso",
                    "given_name": "Cristina",
                    "ORCID": null
                },
                {
                    "url": "http://api.gregory-ms.com/authors/46160/",
                    "family_name": "Oo",
                    "given_name": "Samuel",
                    "ORCID": null
                },
                {
                    "url": "http://api.gregory-ms.com/authors/46161/",
                    "family_name": "Hendricks-Ferguson",
                    "given_name": "Verna L.",
                    "ORCID": null
                },
                {
                    "url": "http://api.gregory-ms.com/authors/46162/",
                    "family_name": "Varni",
                    "given_name": "James W.",
                    "ORCID": "http://orcid.org/0000-0003-4816-4357"
                }
            ],
            "relevant": null,
            "ml_prediction_gnb": false,
            "ml_prediction_lr": false,
            "discovery_date": "2021-05-29T00:20:09Z",
            "noun_phrases": [
                "PedsQL Multiple Sclerosis Module Domain and Item Development",
                "Qualitative Methods"
            ],
            "doi": "10.1177/08830738211015016",
            "access": "restricted",
            "takeaways": " Qualitative methods developed domains and items to support the content validity for the Pediatric Quality of Life Inventory (PedsQL) Multiple Sclerosis Module for youth with pediatric-onset multiple sclerosis . The domains derived include general fatigue, sleep/rest fatigue, cognitive functioning and cognitive functioning ."
        },
        {
            "article_id": 2090,
            "title": "Care consumption of people with multiple sclerosis: A multichannel sequence analysis in a population-based setting in British Columbia, Canada",
            "summary": "<div><p>Mult Scler. 2021 May 28:13524585211016726. doi: 10.1177/13524585211016726. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">BACKGROUND: Persons with multiple sclerosis (PwMS) typically require complex multidisciplinary care, which is rarely formally assessed.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">OBJECTIVES: We applied multichannel sequence analysis (MCSA) to identify care consumption patterns by PwMS in British Columbia, Canada.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">METHODS: We created two cohorts, comprising incident and prevalent MS cases, using linked clinical and administrative data. We applied MCSA to quantify and compare the care pathways of PwMS, based on all-cause hospitalizations and physician visits (divided into five specialities). Care consumption clusters were characterized using demographic and clinical features.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">RESULTS: From 1048 incident and 3180 prevalent PwMS, the MCSA identified 12 and 6 distinct care consumption clusters over a median follow-up of 9.6 and 13.0 years, respectively. Large disparities between clusters were observed; the median number of annual consultations ranged from 5.6 to 21.3 for general practitioners, 1.2 to 4.6 for neurologists and 0 to 5.3 for psychiatrists in the incident cohort. Characteristics at MS symptom onset associated with the highest care consumption included high comorbidity burden and older age. There were similar disparities and associations for prevalent PwMS.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSION: The distinct patterns of care consumption, which were reminiscent of the heterogeneity of MS itself, may facilitate health service planning and evaluation, and provide a novel outcome measure in health research.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34048293/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210528202008&amp;v=2.14.4\">34048293</a> | DOI:<a href=\"https://doi.org/10.1177/13524585211016726\">10.1177/13524585211016726</a></p></div>",
            "link": "https://pubmed.ncbi.nlm.nih.gov/34048293/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x",
            "published_date": "2021-12-19T02:01:56.461000Z",
            "source": "PubMed",
            "publisher": "SAGE Publications",
            "container_title": "Multiple Sclerosis Journal",
            "authors": [
                {
                    "url": "http://api.gregory-ms.com/authors/988/",
                    "family_name": "Roux",
                    "given_name": "Jonathan",
                    "ORCID": "http://orcid.org/0000-0002-0158-2837"
                },
                {
                    "url": "http://api.gregory-ms.com/authors/993/",
                    "family_name": "Leray",
                    "given_name": "Emmanuelle",
                    "ORCID": null
                },
                {
                    "url": "http://api.gregory-ms.com/authors/1572/",
                    "family_name": "Tremlett",
                    "given_name": "Helen",
                    "ORCID": "http://orcid.org/0000-0001-5804-2535"
                },
                {
                    "url": "http://api.gregory-ms.com/authors/1573/",
                    "family_name": "Zhu",
                    "given_name": "Feng",
                    "ORCID": null
                },
                {
                    "url": "http://api.gregory-ms.com/authors/4290/",
                    "family_name": "Kingwell",
                    "given_name": "Elaine",
                    "ORCID": null
                }
            ],
            "relevant": null,
            "ml_prediction_gnb": false,
            "ml_prediction_lr": false,
            "discovery_date": "2021-05-29T00:20:09Z",
            "noun_phrases": [
                "Care consumption",
                "people",
                "multiple sclerosis",
                "A multichannel sequence analysis",
                "a population-based setting",
                "British Columbia",
                "Canada"
            ],
            "doi": "10.1177/13524585211016726",
            "access": "open",
            "takeaways": " Multiple sclerosis typically requires complex multidisciplinary care, which is rarely formally assessed . Multichannel sequence analysis identified 12 and 6 distinct care consumption clusters over a median follow-up of 9.6 and 13.0 years ."
        },
        {
            "article_id": 2089,
            "title": "Nutraceutical and therapeutic potential of Phycocyanobilin for treating Alzheimer&#39;s disease",
            "summary": "<div><p>J Biosci. 2021;46:42.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">Alzheimer's disease (AD) is a devastating neurodegenerative condition provoking the loss of cognitive and memory performances. Despite huge efforts to develop effective AD therapies, there is still no cure for this neurological condition. Here, we review the main biological properties of Phycocyanobilin (PCB), accounting for its potential uses against AD. PCB, given individually or released in vivo from C-Phycocyanin (C-PC), acts as a bioactive-molecule-mediating antioxidant, is anti-inflammatory and has immunomodulatory activities. PCB/C-PC are able to scavenge reactive oxygen and nitrogen species, to counteract lipid peroxidation and to inhibit enzymes such as NADPH oxidase and COX-2. In animal models of multiple sclerosis and ischemic stroke, these compounds induce remyelination as demonstrated by electron microscopy and the expression of genes such as <i>Mal</i> up-regulation of and <i>Lingo-1</i> down-regulation. These treatments also reduce pro-inflammatory cytokines levels and induce immune suppressive genes. PCB/C-PC protects isolated rat brain mitochondria and inactivate microglia, astrocytes and neuronal apoptosis mediators. Such processes are all involved in the pathogenic cascade of AD, and thus PCB may effectively mitigate the injury in this condition. Furthermore, PCB can be administered safely by oral or parenteral routes and therefore, could be commercially offered as a nutraceutical supplement or as a pharmaceutical drug.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34047285/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210528202008&amp;v=2.14.4\">34047285</a></p></div>",
            "link": "https://pubmed.ncbi.nlm.nih.gov/34047285/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x",
            "published_date": "2021-01-01T00:00:00Z",
            "source": "PubMed",
            "publisher": "Springer Science and Business Media LLC",
            "container_title": "Journal of Biosciences",
            "authors": [
                {
                    "url": "http://api.gregory-ms.com/authors/32397/",
                    "family_name": "Pentón-Rol",
                    "given_name": "Giselle",
                    "ORCID": null
                },
                {
                    "url": "http://api.gregory-ms.com/authors/32398/",
                    "family_name": "Marín-Prida",
                    "given_name": "Javier",
                    "ORCID": null
                },
                {
                    "url": "http://api.gregory-ms.com/authors/33615/",
                    "family_name": "Piniella-Matamoros",
                    "given_name": "Beatriz",
                    "ORCID": null
                }
            ],
            "relevant": null,
            "ml_prediction_gnb": false,
            "ml_prediction_lr": false,
            "discovery_date": "2021-05-29T00:20:09Z",
            "noun_phrases": [
                "Nutraceutical and therapeutic potential",
                "Phycocyanobilin",
                "Alzheimer&#39;s disease"
            ],
            "doi": "10.1007/s12038-021-00161-7",
            "access": "restricted",
            "takeaways": " Phycocyanobilin (PCB) acts as a bioactive-molecule-mediating antioxidant, is anti-inflammatory and has immunomodulatory activities . PCB can be administered safely by oral or parenteral routes ."
        },
        {
            "article_id": 2086,
            "title": "The impact of ocrelizumab on health-related quality of life in individuals with multiple sclerosis",
            "summary": "<div><p>Mult Scler J Exp Transl Clin. 2021 May 18;7(2):20552173211007523. doi: 10.1177/20552173211007523. eCollection 2021 Apr-Jun.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">BACKGROUND: Ocrelizumab is approved for the treatment of both relapsing and progressive multiple sclerosis (MS).</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">OBJECTIVE: To examine the impact of ocrelizumab on health-related quality of life (HRQOL) in individuals with MS.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">METHODS: Ninety-eight individuals with relapsing and 32 with progressive MS were enrolled. Participants were administered a battery of patient-reported outcome (PRO) measures at their first ocrelizumab infusion, and infusions at 6 and 12 months. PRO measures included the Medical Outcomes Study SF-36 and Neuro-QoL.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">RESULTS: At baseline, participants had low mean scores across HRQOL domains. After 12 months, increases were observed on SF-36 Role-Physical, General Health, Vitality, Role-Emotional, Mental health and Mental Component Summary. On Neuro-QoL, improvements were seen in Positive Affect, Anxiety, Emotional and Behavioral Dyscontrol and Fatigue. Several demographic and clinical characteristics were associated with HRQOL at baseline. The strongest associations were between physical HRQOL measures and measures of MS disability. Associations between the longitudinal change in HRQOL scores and baseline demographic and clinical characteristics were mild.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSIONS: We observed significant improvements across multiple mental HRQOL domains at 12 months in individuals treated with ocrelizumab. These findings support the use of HRQOL measures to provide a subjective measure of treatment impact that complements traditional outcomes.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34046184/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210528202008&amp;v=2.14.4\">34046184</a> | PMC:<a href=\"https://www.ncbi.nlm.nih.gov/pmc/PMC8138295/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210528202008&amp;v=2.14.4\">PMC8138295</a> | DOI:<a href=\"https://doi.org/10.1177/20552173211007523\">10.1177/20552173211007523</a></p></div>",
            "link": "https://pubmed.ncbi.nlm.nih.gov/34046184/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x",
            "published_date": "2021-05-17T23:00:00Z",
            "source": "PubMed",
            "publisher": "SAGE Publications",
            "container_title": "Multiple Sclerosis Journal - Experimental, Translational and Clinical",
            "authors": [
                {
                    "url": "http://api.gregory-ms.com/authors/3915/",
                    "family_name": "Chitnis",
                    "given_name": "Tanuja",
                    "ORCID": null
                },
                {
                    "url": "http://api.gregory-ms.com/authors/9030/",
                    "family_name": "Zurawski",
                    "given_name": "Jonathan",
                    "ORCID": null
                },
                {
                    "url": "http://api.gregory-ms.com/authors/21792/",
                    "family_name": "Healy",
                    "given_name": "Brian C",
                    "ORCID": null
                },
                {
                    "url": "http://api.gregory-ms.com/authors/33813/",
                    "family_name": "Glanz",
                    "given_name": "Bonnie I",
                    "ORCID": null
                },
                {
                    "url": "http://api.gregory-ms.com/authors/33814/",
                    "family_name": "Weiner",
                    "given_name": "Howard L",
                    "ORCID": null
                },
                {
                    "url": "http://api.gregory-ms.com/authors/46156/",
                    "family_name": "Casady",
                    "given_name": "Emily C",
                    "ORCID": null
                },
                {
                    "url": "http://api.gregory-ms.com/authors/46157/",
                    "family_name": "Shamah",
                    "given_name": "Rebecca",
                    "ORCID": null
                },
                {
                    "url": "http://api.gregory-ms.com/authors/46158/",
                    "family_name": "Weiner",
                    "given_name": "Mira",
                    "ORCID": null
                }
            ],
            "relevant": null,
            "ml_prediction_gnb": false,
            "ml_prediction_lr": false,
            "discovery_date": "2021-05-29T00:20:09Z",
            "noun_phrases": [
                "The impact",
                "ocrelizumab",
                "health-related quality",
                "life",
                "individuals",
                "multiple sclerosis"
            ],
            "doi": "10.1177/20552173211007523",
            "access": "open",
            "takeaways": " Ocrelizumab is approved for the treatment of both relapsing and progressive MS . After 12 months, increases were observed on SF-36 Role-Physical, General Health, Vitality, Role-Emotional, Mental health and Mental Component Summary ."
        },
        {
            "article_id": 2085,
            "title": "Influence of equipment changes on MRI measures of brain atrophy and brain microstructure in a placebo-controlled trial of ibudilast in progressive multiple sclerosis",
            "summary": "<div><p>Mult Scler J Exp Transl Clin. 2021 May 18;7(2):20552173211010843. doi: 10.1177/20552173211010843. eCollection 2021 Apr-Jun.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">BACKGROUND: Hardware changes can be an unavoidable confound in imaging trials. Understanding the impact of such changes may play an important role in the analysis of imaging data.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">OBJECTIVE: To characterize the effect of equipment changes in a longitudinal, multi-site multiple sclerosis trial.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">METHODS: Using data from a clinical trial in progressive multiple sclerosis, we explored how major changes in imaging hardware affected data. We analyzed the extent to which these changes affected imaging biomarkers and the estimated treatment effects by including such changes as a time-dependent covariate.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">RESULTS: Significant differences whole brain atrophy (brain parenchymal fraction, BPF) and microstructure (transverse diffusivity, TD) between scans with and without changes were found and depended on the type of hardware change. A switch from GE HDxt to Siemens Skyra led to significant shifts in BPF (p &lt; 0.04) and TD (p &lt; 0.0001). However, we could not detect the influence of hardware changes on overall trial outcomes- differences between placebo and treatment arms in change over time of BPF and TD (p &gt; 0.5).</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSIONS: The results suggest that differences among hardware types should be considered when planning and analyzing brain atrophy and diffusivity in a longitudinal clinical trial.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34046185/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210528202008&amp;v=2.14.4\">34046185</a> | PMC:<a href=\"https://www.ncbi.nlm.nih.gov/pmc/PMC8138298/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210528202008&amp;v=2.14.4\">PMC8138298</a> | DOI:<a href=\"https://doi.org/10.1177/20552173211010843\">10.1177/20552173211010843</a></p></div>",
            "link": "https://pubmed.ncbi.nlm.nih.gov/34046185/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x",
            "published_date": "2021-05-17T23:00:00Z",
            "source": "PubMed",
            "publisher": "SAGE Publications",
            "container_title": "Multiple Sclerosis Journal - Experimental, Translational and Clinical",
            "authors": [
                {
                    "url": "http://api.gregory-ms.com/authors/321/",
                    "family_name": "Nakamura",
                    "given_name": "Kunio",
                    "ORCID": null
                },
                {
                    "url": "http://api.gregory-ms.com/authors/648/",
                    "family_name": "Fox",
                    "given_name": "Robert J",
                    "ORCID": "http://orcid.org/0000-0002-4263-3717"
                },
                {
                    "url": "http://api.gregory-ms.com/authors/33609/",
                    "family_name": "Sakaie",
                    "given_name": "Ken",
                    "ORCID": "http://orcid.org/0000-0002-5633-4494"
                },
                {
                    "url": "http://api.gregory-ms.com/authors/33610/",
                    "family_name": "Fedler",
                    "given_name": "Janel K",
                    "ORCID": null
                },
                {
                    "url": "http://api.gregory-ms.com/authors/33611/",
                    "family_name": "Yankey",
                    "given_name": "Jon W",
                    "ORCID": null
                },
                {
                    "url": "http://api.gregory-ms.com/authors/33612/",
                    "family_name": "Debbins",
                    "given_name": "Josef",
                    "ORCID": null
                },
                {
                    "url": "http://api.gregory-ms.com/authors/33613/",
                    "family_name": "Lowe",
                    "given_name": "Mark J",
                    "ORCID": null
                },
                {
                    "url": "http://api.gregory-ms.com/authors/33614/",
                    "family_name": "Raska",
                    "given_name": "Paola",
                    "ORCID": null
                }
            ],
            "relevant": null,
            "ml_prediction_gnb": false,
            "ml_prediction_lr": false,
            "discovery_date": "2021-05-29T00:20:09Z",
            "noun_phrases": [
                "Influence",
                "equipment changes",
                "MRI measures",
                "brain atrophy",
                "brain microstructure",
                "a placebo-controlled trial",
                "ibudilast",
                "progressive multiple sclerosis"
            ],
            "doi": "10.1177/20552173211010843",
            "access": "open",
            "takeaways": " Hardware changes can be an unavoidable confound in imaging trials, authors say . Switching from GE HDxt to Siemens Skyra led to significant shifts in brain atrophy and microstructure ."
        },
        {
            "article_id": 2084,
            "title": "Hormones in experimental autoimmune encephalomyelitis (EAE) animal models",
            "summary": "<div><p>Transl Neurosci. 2021 May 6;12(1):164-189. doi: 10.1515/tnsci-2020-0169. eCollection 2021 Jan 1.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS) in which activated immune cells attack the CNS and cause inflammation and demyelination. While the etiology of MS is still largely unknown, the interaction between hormones and the immune system plays a role in disease progression, but the mechanisms by which this occurs are incompletely understood. Several <i>in vitro</i> and <i>in vivo</i> experimental, but also clinical studies, have addressed the possible role of the endocrine system in susceptibility and severity of autoimmune diseases. Although there are several demyelinating models, experimental autoimmune encephalomyelitis (EAE) is the oldest and most commonly used model for MS in laboratory animals which enables researchers to translate their findings from EAE into human. Evidences imply that there is great heterogeneity in the susceptibility to the induction, the method of induction, and the response to various immunological or pharmacological interventions, which led to conflicting results on the role of specific hormones in the EAE model. In this review, we address the role of endocrine system in EAE model to provide a comprehensive view and a better understanding of the interactions between the endocrine and the immune systems in various models of EAE, to open up a ground for further detailed studies in this field by considering and comparing the results and models used in previous studies.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34046214/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210528202008&amp;v=2.14.4\">34046214</a> | PMC:<a href=\"https://www.ncbi.nlm.nih.gov/pmc/PMC8134801/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210528202008&amp;v=2.14.4\">PMC8134801</a> | DOI:<a href=\"https://doi.org/10.1515/tnsci-2020-0169\">10.1515/tnsci-2020-0169</a></p></div>",
            "link": "https://pubmed.ncbi.nlm.nih.gov/34046214/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x",
            "published_date": "2021-05-05T23:00:00Z",
            "source": "PubMed",
            "publisher": "Walter de Gruyter GmbH",
            "container_title": "Translational Neuroscience",
            "authors": [
                {
                    "url": "http://api.gregory-ms.com/authors/2670/",
                    "family_name": "Ghareghani",
                    "given_name": "Majid",
                    "ORCID": null
                },
                {
                    "url": "http://api.gregory-ms.com/authors/2672/",
                    "family_name": "Zibara",
                    "given_name": "Kazem",
                    "ORCID": null
                },
                {
                    "url": "http://api.gregory-ms.com/authors/33467/",
                    "family_name": "Ghanbari",
                    "given_name": "Amir",
                    "ORCID": null
                },
                {
                    "url": "http://api.gregory-ms.com/authors/33605/",
                    "family_name": "Eid",
                    "given_name": "Ali",
                    "ORCID": null
                },
                {
                    "url": "http://api.gregory-ms.com/authors/33606/",
                    "family_name": "Shaito",
                    "given_name": "Abdullah",
                    "ORCID": null
                },
                {
                    "url": "http://api.gregory-ms.com/authors/33607/",
                    "family_name": "Mohamed",
                    "given_name": "Wael",
                    "ORCID": null
                },
                {
                    "url": "http://api.gregory-ms.com/authors/33608/",
                    "family_name": "Mondello",
                    "given_name": "Stefania",
                    "ORCID": null
                }
            ],
            "relevant": null,
            "ml_prediction_gnb": false,
            "ml_prediction_lr": false,
            "discovery_date": "2021-05-29T00:20:09Z",
            "noun_phrases": [
                "Hormones",
                "experimental autoimmune encephalomyelitis",
                "(EAE) animal models"
            ],
            "doi": "10.1515/tnsci-2020-0169",
            "access": "open",
            "takeaways": " Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system . The interaction between hormones and the immune system plays a role in disease progression, but the mechanisms are incompletely understood ."
        },
        {
            "article_id": 2083,
            "title": "Fantastic IgA plasma cells and where to find them",
            "summary": "<div><p>Immunol Rev. 2021 May 27. doi: 10.1111/imr.12980. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">IgA is produced in large quantities at mucosal surfaces by IgA<sup>+</sup> plasma cells (PC), protecting the host from pathogens, and restricting commensal access to the subepithelium. It is becoming increasingly appreciated that IgA<sup>+</sup> PC are not constrained to mucosal barrier sites. Rather, IgA<sup>+</sup> PC may leave these sites where they provide both host defense and immunoregulatory function. In this review, we will outline how IgA<sup>+</sup> PC are generated within the mucosae and how they subsequently migrate to their \"classical\" effector site, the gut lamina propria. From there we provide examples of IgA<sup>+</sup> PC displacement from the gut to other parts of the body, referencing examples during homeostasis and inflammation. Lastly, we will speculate on mechanisms of IgA<sup>+</sup> PC displacement to other tissues. Our aim is to provide a new perspective on how IgA<sup>+</sup> PC are truly fantastic beasts of the immune system and identify new places to find them.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34046908/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210528202008&amp;v=2.14.4\">34046908</a> | DOI:<a href=\"https://doi.org/10.1111/imr.12980\">10.1111/imr.12980</a></p></div>",
            "link": "https://pubmed.ncbi.nlm.nih.gov/34046908/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x",
            "published_date": "2021-01-09T00:00:00Z",
            "source": "PubMed",
            "publisher": "Wiley",
            "container_title": "Immunological Reviews",
            "authors": [
                {
                    "url": "http://api.gregory-ms.com/authors/4737/",
                    "family_name": "Gommerman",
                    "given_name": "Jennifer L.",
                    "ORCID": "http://orcid.org/0000-0003-4576-6168"
                },
                {
                    "url": "http://api.gregory-ms.com/authors/24050/",
                    "family_name": "Isho",
                    "given_name": "Baweleta",
                    "ORCID": null
                },
                {
                    "url": "http://api.gregory-ms.com/authors/36603/",
                    "family_name": "Florescu",
                    "given_name": "Alexandra",
                    "ORCID": "http://orcid.org/0000-0001-6652-6863"
                },
                {
                    "url": "http://api.gregory-ms.com/authors/36604/",
                    "family_name": "Wang",
                    "given_name": "Angela A.",
                    "ORCID": "http://orcid.org/0000-0001-6991-7368"
                }
            ],
            "relevant": null,
            "ml_prediction_gnb": false,
            "ml_prediction_lr": false,
            "discovery_date": "2021-05-29T00:20:09Z",
            "noun_phrases": [
                "Fantastic IgA plasma cells",
                "them"
            ],
            "doi": "10.1111/imr.12980",
            "access": "restricted",
            "takeaways": " IgA+ plasma cells protect the host from pathogens and restrict commensal access to the subepithelium . They may leave mucosal barrier sites to provide host defense and immunoregulatory function ."
        },
        {
            "article_id": 2082,
            "title": "Disease-modifying therapy for multiple sclerosis",
            "summary": "<div><p>Tidsskr Nor Laegeforen. 2021 May 10;141(8). doi: 10.4045/tidsskr.21.0155. Print 2021 May 25.</p><p><b>NO ABSTRACT</b></p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34047171/?utm_source=Other&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&amp;fc=20210216052009&amp;ff=20210528202008&amp;v=2.14.4\">34047171</a> | DOI:<a href=\"https://doi.org/10.4045/tidsskr.21.0155\">10.4045/tidsskr.21.0155</a></p></div>",
            "link": "https://pubmed.ncbi.nlm.nih.gov/34047171/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x",
            "published_date": "2021-05-09T23:00:00Z",
            "source": "PubMed",
            "publisher": "Norwegian Medical Association",
            "container_title": "Tidsskrift for Den norske legeforening",
            "authors": [
                {
                    "url": "http://api.gregory-ms.com/authors/2645/",
                    "family_name": "Myhr",
                    "given_name": "Kjell-Morten",
                    "ORCID": null
                },
                {
                    "url": "http://api.gregory-ms.com/authors/5725/",
                    "family_name": "Bø",
                    "given_name": "Lars",
                    "ORCID": null
                },
                {
                    "url": "http://api.gregory-ms.com/authors/6913/",
                    "family_name": "Holmøy",
                    "given_name": "Trygve",
                    "ORCID": null
                },
                {
                    "url": "http://api.gregory-ms.com/authors/11437/",
                    "family_name": "Nygaard",
                    "given_name": "Gro Owren",
                    "ORCID": null
                }
            ],
            "relevant": null,
            "ml_prediction_gnb": false,
            "ml_prediction_lr": false,
            "discovery_date": "2021-05-29T00:20:09Z",
            "noun_phrases": [
                "Disease-modifying therapy",
                "multiple sclerosis"
            ],
            "doi": "10.4045/tidsskr.21.0155",
            "access": "open",
            "takeaways": ""
        }
    ]
}